MAP2K7 and thyroid gland papillary carcinoma: In another in vitro experiment, combining the HER inhibitor lapatinib with BRAF/MEK inhibitors dabrafenib/selumetinib significantly enhanced redifferentiation in BRAFV600E-mutant papillary thyroid cancer cells compared to BRAF/MEK inhibition alone (73).